insights_auto
Why is IMMP down 8.11%?
Dive Deeperchevron_right
IMMP:NASDAQ
Immutep Ltd - ADR
$3.06
arrow_downward
-8.11%(-0.27) 1D
Oct 30, 3:00:00 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for IMMP...
Open
$3.30
High
$3.30
Low
$3.05
Mkt. cap
23.82M
Avg. vol.
107.57K
Volume
13.00
52-wk high
$70.60
52-wk low
$3.05
EPS
-$7.58
Beta
2.32
Shares outstanding
7.37M
No. of employees
19
Open
$3.30
High
$3.30
Low
$3.05
Mkt. cap
23.82M
Avg. vol.
107.57K
Volume
13.00
52-wk high
$70.60
52-wk low
$3.05
EPS
-$7.58
Beta
2.32
Shares outstanding
7.37M
No. of employees
19
News stories
From web sources and news partners
FXStreet
·
56 minutes ago
Dow Jones futures advance as risk appetite rebounds ahead of busy week
AOL.com
·
41 minutes ago
Stock market today: Dow, S&P 500, Nasdaq futures recover from bruising sell-off ahead of busy week
BigGo Finance
·
23 hours ago
Nasdaq's 5.3% October Swoon: AI Capex Fears Meet a History of 24% Rebound Years
BeInCrypto
·
5 hours ago
Bitcoin 39% Below Peak, Meme Coins Down Up to 99%, but S&P 500 Near Record
Profile
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Prima currently has three main products in its pipeline, all acquired with Immutep:
Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.
IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.
IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis. Wikipedia
About Immutep Ltd - ADR